# A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

> **NCT05044195** · PHASE3 · COMPLETED · sponsor: **Seqirus** · enrollment: 2044 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** aQIV
- **BIOLOGICAL:** Comparator QIV

## Key facts

- **NCT ID:** NCT05044195
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-01-18
- **Final completion:** 2022-09-09
- **Target enrollment:** 2044 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05044195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05044195, "A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05044195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*